Researches

South Egypt Cancer Institute

Assiut University

# Title Department Research Member Research Year
11 Analgesic effect of nulbuphine -bupivacaine combination in ultrasound guided Transverses abdominis plane block in patients undergoing major abdominal cancer surgeries. Department of Anesthesia, Intensive care and Pain management Dr. Rania Mohamed Abd-Elemam 2024
12 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Shimaa Hassan Shabaan Hassan 2024
13 Beta Endorphins, Interleukin 1 and Interleukin 38 in Covid Patients Associated with Neuropsychological Manifestations Department of Clinical Pathology Prof. Eman Massad Zaki El-Hefny 2024
14 Diagnostic efficacy of Ovarian-Adnexal Reporting and Data System (ORADS) in Evaluation of Ovarian Lesions Department of Radiology Dr. Doaa Mohamed Fouad Mahmoud 2024
15 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Amen Hamdy Zaki Ali 2024
16 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Salah Mabrouk Khallaf Abd Rabou 2024
17 Analgesic effect of nulbuphine -bupivacaine combination in ultrasound guided Transverses abdominis plane block in patients undergoing major abdominal cancer surgeries. Department of Anesthesia, Intensive care and Pain management اميرة محمد عثمان محمد 2024
18 Measurement and Evaluation of the Impact of a Carbon Fiber Couch in Radiation Oncology Department of Radiotherapy and Nuclear medicine Dr- Mostafa Ahmed Hashem Soliman 2024
19 The transcription factor ZEB-1 conveys chemoresistance in breast cancer Department of Medical Oncology Samar Abotaleb Mahmou 2024
20 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Amany Mohammed Abdel Moatamed 2024